View Older Stories View More Recent Stories
-
Roth Capital Reiterates Buy on Motorcar Parts of America (MPAA) After Visiting Headquarters
-
Roth Capital Upgrades ANI Pharmaceuticals (ANIP) to Buy
-
Pioneer Power (PPSI) Prices 1.125M Common Share Offering at $4
-
Pioneer Prices Underwritten Public Offering of Common Stock
-
Major Overhang for ImmunoCellular (IMUC) Removed with CIRM Grant - Roth Capital
-
Roth Capital Reiterates Buy on GigOptix (GIG) Following Terasquare Acquisition
-
Conatus Pharmaceuticals (CNAT) Bullish Stance Reiterated at Roth Capital Following Data
-
ESSA Pharma (EPIX) Bullish View Reiterated at Roth Capital Following IND Okay
-
Roth Affirms Neogen (NEOG) at 'Buy'; Developing Market Efforts Should Outpace FX Issues
-
Roth Positive on Motorcar Parts of America (MPAA) Following AutoZone's (AZO) Q4 Results
-
Roth Capital Raises Price Target on Concert Pharma (CNCE) Following CTP-656 Data
-
Roth Capital Raised Price Target on AcelRx Pharma (ACRX) Following Announced Monetization Agreement
-
Roth Capital Reiterates Buy on Cherokee (CHKE) Following U.K. Store Tours
-
Strongbridge Biopharma plc Announces Launch of Its Proposed Initial U.S. Public Offering
-
Strongbridge Biopharma (SBBP) Sees IPO Offering Size of 4.25M Shares
-
Roth Capital Reiterates Buy on Sky Solar Holdings (SKYS) Following Announced Partnership with Hudson Clean Energy Partners
-
Early Read on unique BV (QURE) Sanfilippo B Trial 'Encouraging', Roth Capital Says
-
Pioneer Announces Proposed Public Offering of Common Stock
-
Roth Capital Reiterates Buy on Daqo New Energy (DQ) Following Investor Meetings
-
Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares
-
Sun Basket Announces $4.5 Million In Venture Funding Led by PivotNorth Capital and Baseline Ventures
-
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Ublituximab Combo SPA Validates Study Design
-
Roth Capital Affirms Lion Bio (LBIO) at 'Buy' Following Positive TIL Phase 2 Data in Metastatic Melanoma
-
Notable 52-Week Highs and Lows 9/16: (ITCI) (COLL) (UA) High; (GBSN) (XNPT) (NR) Low
-
Roth Capital Downgrades Adept Technology (ADEP) to Neutral Amid Takeover
-
Great Basin Announces Retention of Roth Capital Partners as Financial Advisor in Restructuring of the Company’s Series C Warrants
-
Roth Capital Recommends Buying bluebird bio (BLUE) Into ASH
-
The Sheckler Foundation's 8th Annual Celebrity Golf Tournament Raised $300,000 to Empower Those in Need
-
Roth Capital Raises Price Target on Quicklogic Corp (QUIK) on Continuing Design Win Momentum
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy' Following Scleradec-I Trial Results; Data Bodes Well for Pivotal Program
-
Roth Capital Reiterates Buy on Nektar Therapeutics (NKTR) After Meeting with Management
-
Roth Reaffirms Applied Genetic (AGTC) at 'Buy' Following FY15 Results; Fundamental Thesis Remains Unchanged
-
Roth Capital Starts Intec Pharma Ltd. (NTEC) at Buy
-
GigOptix, Inc. Closes Public Offering of Common Stock to Support Enhanced Strategic Growth Through Acquisitions
-
Roth Affirms Power Solutions (PSIX) at 'Buy' as Shares Retake Key Multiple Level
-
Roth Capital Cuts Price Target on PriceSmart (PSMT) As Comps Hold in High-Single-Digits
-
Roth Capital Reiterates Buy on Aduro Biotech (ADRO) Following Announced Incyte (INCY) Collaboration
-
Notable Analyst Rating Changes 9/9: (GS) (CIEN) (WBA) Upgraded; (MNKD) (GOL) (MOBL) Downgraded
-
Roth Capital Downgrades Quiksilver (ZQK) to Sell
-
Roth Capital reiterated remains Bullish on Roth Capital Sequential Brands (SQBG) Following signed Licensing Agreement
-
Roth Capital Downgrades Yingli Green Energy (YGE) to Sell
-
Sphere 3D to Participate at ROTH Datacenter Technology Corporate Access Day in San Francisco on September 9, 2015
-
Roth Capital Remains Bullish on Plantronics (PLT) Following Investor Day
-
Roth Capital Sees Attractive Risk/Reward for uniQure (QURE) Into Sanfilippo Abstract
-
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
-
InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
-
BIO Announces Presenting Companies for 14th Annual BIO Investor Forum
-
Roth Capital Affirms Sarepta (SRPT) at 'Buy'; Shapeshifting Bears Back to Where It Started
-
Roth Capital Reiterates Buy on Performance Sports Group (PSG) Following Analyst and Investor Event
-
Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals

